Protocol Ledger

NCT05054751 · Phase III · COMPLETED

GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer

Interventional Phase III clinical trial protocol NCT05054751 sponsored by Genor Biopharma Co in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-09-10 Enrollment: 275 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05054751
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)275 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05054751
Protocol FieldVerified Registry Value
NCT IdentifierNCT05054751
Consolidated Lead SponsorGenor Biopharma Co
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment275 participants (ACTUAL)
Registered Start Date2021-09-10
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI